The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier position is being challenged by the IL-17 inhibitors secukinumab (Novartis’s Cosentyx), ixekizumab (Eli Lilly’s Taltz), and brodalumab (Bausch Health’s Siliq, Leo Pharma’s Kyntheum, Kyowa Hakko Kirin’s Lumicef) and by the IL-12/23 inhibitor ustekinumab (Janssen’s Stelara). With the approvals of the IL-23 inhibitors guselkumab (Janssen’s Tremfya), tildrakizumab (Merck & Co. / Almirall / Sun Pharma’s Ilumya / Ilumetri), and, more recently, risankizumab (AbbVie / Boehringer Ingelheim’s Skyrizi), another effective drug class has been introduced to this competitive market. The landscape for the established biologics will change even further with the increasing availability and use of biosimilars.

Questions answered:

  • How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors Cosentyx, Taltz, and Siliq / Kyntheum / Lumicef and the emerging IL-17 A/F dual inhibitor, UCB’s bimekizumab, and where are / will these agents be positioned in the psoriasis treatment algorithm?
  • What will be the impact of the IL-23 inhibitors Tremfya, Ilumya, Skyrizi, and Eli Lilly's emerging therapy mirikizumab, and how will they fare in the competitive psoriasis market?
  • How is the oral agent apremilast (Amgen’s Otezla) used to treat psoriasis, and how will it  compare to BMS's emerging oral TYK2 inhibitor, BMS-986165?
  • How fast will uptake of biosimilars occur in psoriasis, and which brands will see the most erosion in patient share and sales?

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 24 country-specific interviews with thought leaders. Supported by survey data collected for this and other DRG research.

Epidemiology: Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.

Emerging therapies: Phase III/PR: 7 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.

Forecast: 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2029, segmented by brands/generics and epidemiological subpopulations.

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Mohit Nasa, MBA; T.J. Arndt, MPH, CPH

Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis.

He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.

T.J. joined Decision Resources Group in 2018 as an entry-level epidemiologist and previously worked in basic sciences research academia.

T.J. earned his Masters in Public Health from the University of Florida, where he conducted an internship focused on developing a clinical model to non-invasively screen for Non-Alcoholic Steatohepatitis (NASH). He also holds a B.S. in Microbiology & Cell Science and a B.A. in Spanish, both from the University of Florida. During his undergraduate and graduate career, he worked in two physiology-based research labs at the University of Florida, focusing on maternal and fetal stresses during pregnancy and parturition.

Related Reports

Psoriasis - Access & Reimbursement - Detailed, Expanded Analysis (US)

This report is available to find out more click the link and fill out the form to get more details.

View Details

Psoriasis - Current Treatment - Detailed, Expanded Analysis (EU5)

Multiple treatment options

View Details

Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

View Details

Psoriasis - Emerging Therapies - Skyrizi Launch Tracking Wave 3 (US)

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Jan...

View Details